Stocktoria
Cytek Biosciences, Inc. CTKB
Cytek Biosciences, Inc. (CTKB) earns a Piotroski F-score of 3/9 (weak financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $201.5M at a -33.0% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -3.27 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.681 |
| Retained earnings / assets | -0.22 |
| EBIT / assets | -0.087 |
| Equity / liabilities | 2.853 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| CTKB | Cytek Biosciences, Inc. | 3/9 | 6.15 | — | +0.5% |
| PACB | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. | 3/9 | -13.42 | — | +3.9% |
| QTRX | Quanterix Corp | 1/9 | -1.83 | — | +1.1% |
| HBIO | HARVARD BIOSCIENCE INC | 4/9 | -10.45 | — | -8.1% |
| PRPO | Precipio, Inc. | 7/9 | -13.13 | — | +28% |
| RPID | RAPID MICRO BIOSYSTEMS, INC. | 2/9 | — | — | +19.7% |
| EYPT | EyePoint, Inc. | 1/9 | -3.58 | — | -27.5% |
About Cytek Biosciences, Inc.
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies using phenotyping approaches; enhanced small particle detection; Cytek amnis imagestream imaging flow cytometers; Cytek guava muse cell analyzers; Cytek muse micro cell analyzers; Cytek guava easyCyte flow cytometers; and Cytek orion reagent cocktail preparation systems. It also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments. In addition, the company offers automated micro-sampling system and automated sample loader system, an automated loaders designed to integrate seamlessly into the Cytek aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for Cytek aurora, northern lights, and Cytek aurora evo systems; and customer support tools. Further, it provides conventional flow and image-based flow cytometry instrumentation and related products and services under the Amnis and Guava brand names. The company serves pharmaceutical and biopharma companies, academic research centers, and contract research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in Europe, Latin America, and the Middle East countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
FAQ
Is CTKB financially healthy?
Cytek Biosciences, Inc.'s Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does CTKB pay a dividend?
No, Cytek Biosciences, Inc. does not currently pay a dividend.
How profitable is CTKB?
In FY2025, Cytek Biosciences, Inc. had a net margin of -33.0% and a return on equity of -19.5%.
What is the analyst price target for CTKB?
The average Wall-Street price target for Cytek Biosciences, Inc. is $5.69, about 19.0% above the recent price, from 4 analysts.
Is CTKB a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Cytek Biosciences, Inc.: a Piotroski F-score of 3/9, an Altman Z″ in the safe zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.